Survey of prescriber understanding of specific risks associated with TROBALT (201426)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/42090
• EU PAS number:
  EUPAS6186
• Study ID:
  42090
• Official title and acronym:
  Survey of prescriber understanding of specific risks associated with TROBALT (201426)
• DARWIN EU® study:
  No
• Study countries:
  Austria

  Belgium

  Bulgaria

  France

  Hong Kong

  Italy

  Norway

  Poland

  Slovenia

  Spain

  Switzerland

  United Kingdom
• Study status:
  Finalised

Research institutions and networks

Institutions

GlaxoSmithKline (GSK)

Study timelines

Date when funding contract was signed

Planned: 14/02/2014

Actual: 14/02/2014

Study start date

Planned: 14/02/2014

Actual: 14/02/2014

Date of final study report

Planned: 06/04/2015

Actual: 26/08/2015

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

GlaxoSmithKline

Study protocol

Initial protocol

prj2250-protocol-redact

Updated protocol

201426-protocol-amend-redact

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)